ATE526345T1 - Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit - Google Patents
Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheitInfo
- Publication number
- ATE526345T1 ATE526345T1 AT06790622T AT06790622T ATE526345T1 AT E526345 T1 ATE526345 T1 AT E526345T1 AT 06790622 T AT06790622 T AT 06790622T AT 06790622 T AT06790622 T AT 06790622T AT E526345 T1 ATE526345 T1 AT E526345T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody
- diagnosis
- prevention
- treatment
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71240005P | 2005-08-31 | 2005-08-31 | |
| PCT/CA2006/001444 WO2007025385A1 (en) | 2005-08-31 | 2006-08-31 | Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE526345T1 true ATE526345T1 (de) | 2011-10-15 |
Family
ID=37808437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06790622T ATE526345T1 (de) | 2005-08-31 | 2006-08-31 | Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8759029B2 (de) |
| EP (1) | EP1937827B1 (de) |
| JP (1) | JP5242396B2 (de) |
| AT (1) | ATE526345T1 (de) |
| CA (1) | CA2620351C (de) |
| DK (1) | DK1937827T3 (de) |
| ES (1) | ES2374102T3 (de) |
| WO (1) | WO2007025385A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1668369B1 (de) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitopschutztest und verfahren zum nachweis von proteinkonformationen |
| US7887803B2 (en) | 2005-12-02 | 2011-02-15 | Amorfix Life Sciences | Methods and compositions to treat misfolded-SOD1 mediated diseases |
| US7794692B2 (en) | 2005-12-02 | 2010-09-14 | Amorfix Life Sciences Ltd. | Methods and compositions for detecting amyotrophic lateral sclerosis |
| EP2495327B1 (de) * | 2006-03-03 | 2016-09-28 | ProMIS Neurosciences Inc. | Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen |
| US8758287B2 (en) | 2008-11-12 | 2014-06-24 | Marv Enterprises, LLC | Utilization of stents for the treatment of blood borne carcinomas |
| WO2010107789A1 (en) * | 2009-03-17 | 2010-09-23 | Marv Enterprises Llc | Sequential extracorporeal treatment of bodily fluids |
| CN102869775A (zh) | 2009-09-30 | 2013-01-09 | 哈佛大学校长及研究员协会 | 通过调节自噬抑制基因产物调节自噬的方法 |
| JP5828521B2 (ja) * | 2010-05-13 | 2015-12-09 | 国立大学法人 東京大学 | 筋萎縮性側索硬化症（ａｌｓ）の診断のための抗体 |
| AU2011320612A1 (en) | 2010-10-26 | 2013-06-13 | University Of Massachusetts | Anti-SOD1 antibodies and uses thereof |
| CN103380145B (zh) | 2010-12-17 | 2016-10-12 | 生物控股有限公司 | 人类抗-sod1抗体 |
| CN113508135A (zh) | 2018-10-29 | 2021-10-15 | 比奥根Ma公司 | 增强血脑屏障转运的人源化和稳定化的fc5变体 |
| WO2023033050A1 (ja) * | 2021-09-02 | 2023-03-09 | 国立大学法人京都大学 | ボルナウイルスベクターを利用した医薬組成物 |
| WO2023033049A1 (ja) * | 2021-09-02 | 2023-03-09 | 国立大学法人滋賀医科大学 | 筋萎縮性側索硬化症の原因となる変異型ｓｏｄ１タンパク質に結合性を有する抗体及び抗体断片 |
| CN113774089A (zh) * | 2021-10-11 | 2021-12-10 | 深圳大学 | 肌萎缩侧索硬化细胞模型细胞株的构建方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4940659A (en) | 1987-02-20 | 1990-07-10 | Monoclonetics International, Inc. | Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome |
| US5843641A (en) | 1993-02-26 | 1998-12-01 | Massachusetts Institute Of Technology | Methods for the daignosis, of familial amyotrophic lateral sclerosis |
| US5780489A (en) | 1996-08-21 | 1998-07-14 | Brooks; Benjamin Rix | Method for treating amyotrophic lateral sclerosis |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| EP1668369B1 (de) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitopschutztest und verfahren zum nachweis von proteinkonformationen |
-
2006
- 2006-08-31 DK DK06790622.2T patent/DK1937827T3/da active
- 2006-08-31 US US12/065,403 patent/US8759029B2/en not_active Expired - Fee Related
- 2006-08-31 ES ES06790622T patent/ES2374102T3/es active Active
- 2006-08-31 JP JP2008528307A patent/JP5242396B2/ja not_active Expired - Fee Related
- 2006-08-31 WO PCT/CA2006/001444 patent/WO2007025385A1/en active Application Filing
- 2006-08-31 AT AT06790622T patent/ATE526345T1/de active
- 2006-08-31 EP EP06790622A patent/EP1937827B1/de active Active
- 2006-08-31 CA CA2620351A patent/CA2620351C/en not_active Expired - Fee Related
-
2014
- 2014-05-27 US US14/288,374 patent/US9266963B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1937827B1 (de) | 2011-09-28 |
| WO2007025385A1 (en) | 2007-03-08 |
| JP2009507475A (ja) | 2009-02-26 |
| US9266963B2 (en) | 2016-02-23 |
| DK1937827T3 (da) | 2012-01-23 |
| EP1937827A4 (de) | 2009-02-18 |
| CA2620351C (en) | 2015-04-21 |
| US20140341927A1 (en) | 2014-11-20 |
| EP1937827A1 (de) | 2008-07-02 |
| CA2620351A1 (en) | 2007-03-08 |
| US8759029B2 (en) | 2014-06-24 |
| ES2374102T3 (es) | 2012-02-13 |
| US20090068194A1 (en) | 2009-03-12 |
| JP5242396B2 (ja) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE526345T1 (de) | Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit | |
| PH12011502389A1 (en) | Monoclonal antibody | |
| MA30632B1 (fr) | Anticorps humanisé | |
| MX2009013503A (es) | Anticuerpo monoclonal anti-amiloide-beta. | |
| MX2009005743A (es) | Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab. | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| WO2008060364A3 (en) | Humani zed antibody against amyloid beta | |
| WO2007011907A3 (en) | Alpha-synuclein antibodies and methods related thereto | |
| WO2008150946A8 (en) | HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF | |
| SG10201407388XA (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| WO2010144711A3 (en) | Immunological targeting of pathological tau proteins | |
| NZ621483A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
| MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
| EA200870050A1 (ru) | Анти-il-17-антитела | |
| WO2006040153A3 (en) | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| EA201100231A1 (ru) | Диагностический анализ на основе антител | |
| MA33825B1 (fr) | Analogue du peptide d'oxyntomoduline | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| EA200900831A1 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов | |
| EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo | |
| EA201070539A1 (ru) | НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| WO2019016247A3 (en) | Agents, uses and methods for treatment | |
| UA102368C2 (ru) | СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1937827 Country of ref document: EP |